EYLEA enables proactive therapy approved for multiple retinal diseases.
EYLEA is the only anti-angiogenic therapy that inhibits vascular endothelial growth factor A (VEGF-A) and Placental Growth Factor (PlGF).
EYLEA's license may allow for a proactive, treat-and-extend dosing approach that is approved for the treatment of:
MD, MBA, DPBO, FPAO, FPCS
Dr. Manolette Roque is a specialist in uveitis, cataract, and refractive surgery. His private practice began in 2000, after his post-graduate fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, in Boston, Massachusetts, USA. His patients are mostly adults who desire spectacle independence. His advocacy includes taking care of individuals with ocular inflammatory diseases.
Everyone deserves the best eye care possible.